{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9"},{"groupId":"OG001","value":"0.0"}]}],"title":"Complete response (CR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.2"},{"groupId":"OG001","value":"9.3"}]}],"title":"Partial response (PR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.0"},{"groupId":"OG001","value":"15.7"}]}],"title":"Minimal response (MR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.4"},{"groupId":"OG001","value":"46.3"}]}],"title":"Stable disease (SD)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.2"},{"groupId":"OG001","value":"15.7"}]}],"title":"Progressive disease (PD)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.3"},{"groupId":"OG001","value":"13.0"}]}],"title":"Not evaluable"}],"denoms":[{"counts":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"108"}],"units":"Participants"}],"description":"IRAC used EBMT criteria to assess myeloma response:\n\n* Complete Response (CR)-absence of serum and urine monoclonal paraprotein for 6 weeks, plus no increase in size or number of lytic bone lesions, plus other factors)\n* Partial Response (PR)-not all CR criteria, plus \\>=50% reduction in serum monoclonal paraprotein plus others\n* Minimal Response (MR)- 25-49% reduction in serum monoclonal paraprotein plus others\n* Stable Disease (SD)- not MR or progressive disease (PD)\n* Progressive Disease (PD)- reappearance of monoclonal paraprotein, lytic bone lesions, other\n* Not Evaluable (NE).\n\nData collection is ongoing and future data results will be included as available.","groups":[{"description":"Combination therapy of 4 mg pomalidomide given once per day on Days 1-21 of each 28-day cycle and the starting dose of dexamethasone (either 40mg or 20 mg) on days 1, 8, 15, and 22 of each 28-day cycle.","id":"OG000","title":"Phase 2: Pomalidomide + Dexamethasone"},{"description":"4 mg pomalidomide was given once per day on Days 1-21 of each 28-day cycle until PD. Participants in the single agent pomalidomide treatment arm who developed confirmed PD at any time had the option to receive oral dexamethasone at the starting dose in addition to their current dose of pomalidomide or to discontinue treatment.","id":"OG001","title":"Phase 2: Pomalidomide"}],"paramType":"NUMBER","populationDescription":"Intent to treat population.\n\nData collection is ongoing and future data results will be included as available.","reportingStatus":"POSTED","timeFrame":"up to 70 weeks","title":"Phase 2: Summary of Best Myeloma Response As Assessed by Independent Response Adjudication Committee (IRAC) Using European Group for Blood and Bone Marrow Transplant (EBMT) Criteria as of the 01 April 2011 Cut-off","type":"SECONDARY","unitOfMeasure":"percentage of participants"}